EXO-CD24

DRUG2 trials

Sponsors

Tel-Aviv Sourasky Medical Center, Nano24med

Conditions

ARDSSARS-CoV-2

Phase 1

Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection

Tel-Aviv Sourasky Medical CenterSARS-CoV-2

Start: 2020-09-25End: 2021-03-25Target: 35Updated: 2021-03-04

Phase 2

Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS

Start: 2023-07-04End: 2025-12-20Target: 90Updated: 2023-07-27

Related Papers

1153. Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-blinded Study.

Open Forum Infectious Diseases2022-12-013 citations